VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients

OBJECTIVE: At present, maintenance therapy with the antiangiogenic agent bevacizumab or with PARP-inhibitors represent two options for BRCA-wildtype ovarian cancer patients, after platinum-based first line chemotherapy. The identification of molecular markers to predict patient response to different...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yi, Oliveira-Ferrer, Leticia, Vettorazzi, Eike, Legler, Karen, Milde-Langosch, Karin, Woelber, Linn, Jaeger, Anna, Prieske, Katharina, Mueller, Volkmar, Schmalfeldt, Barbara, Kuerti, Sascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187059/
https://www.ncbi.nlm.nih.gov/pubmed/35687576
http://dx.doi.org/10.1371/journal.pone.0269680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187059/
https://www.ncbi.nlm.nih.gov/pubmed/35687576
http://dx.doi.org/10.1371/journal.pone.0269680

Ejemplares similares